Condensed pyridine derivatives useful as potent inhibitors of the protein kinase CK2

US8686144B2 · kind B2 · utility

Assignees

• COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• INSTITUT CURIE · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

• Claude Cochet · Le Pont-de-Claix, FR
• Renaud Prudent · Criel de Renage, FR
• Virginie MOUCADEL · Saint-Égrève, FR
• Chi-Hung N'Guyen · Antony, FR

Key dates

• Filing date: Jul 28, 2010
• Grant date: Apr 1, 2014
• Expiry date: Jul 28, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of specific compounds of formula (I) and their pharmaceutically-acceptable salts: (Formula 1) (I) as a new family of protein kinase CK2 inhibitors; the invention also relates to the use of compounds of formula (I) for the preparation of pharmaceutical compositions for the prevention and/or treatment of disorders and/or diseases chosen amongst cancers; autoimmune and inflammatory diseases; infectious diseases; diabetes angiogenesis related disorders; retinopathies and cardiac hypertrophy.